MCID: ADN009
MIFTS: 51

Adenosquamous Carcinoma malady

Categories: Cancer diseases

Aliases & Classifications for Adenosquamous Carcinoma

Aliases & Descriptions for Adenosquamous Carcinoma:

Name: Adenosquamous Carcinoma 12 14 69
Mixed Adenocarcinoma and Squamous Carcinoma 12
Adenosquamous Cell Carcinoma 12
Carcinoma, Adenosquamous 42
Carcinoma Adenosquamous 52

Classifications:



External Ids:

Disease Ontology 12 DOID:4830
MeSH 42 D018196
NCIt 47 C3727
SNOMED-CT 64 403902008 59367005
UMLS 69 C0206623

Summaries for Adenosquamous Carcinoma

Disease Ontology : 12 A squamous cell carcinoma that contains squamous cells and gland-like cells.

MalaCards based summary : Adenosquamous Carcinoma, also known as mixed adenocarcinoma and squamous carcinoma, is related to gastrointestinal stromal tumor and glassy cell variant cervical adenosquamous carcinoma. An important gene associated with Adenosquamous Carcinoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Glioma and MAPK signaling pathway. The drugs Cisplatin and Hematinics have been mentioned in the context of this disorder. Affiliated tissues include pancreas, lung and cervix, and related phenotypes are growth/size/body region and digestive/alimentary

Wikipedia : 71 Adenosquamous carcinoma is a type of cancer that contains two types of cells: squamous cells (thin, flat... more...

Related Diseases for Adenosquamous Carcinoma

Diseases related to Adenosquamous Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 220)
id Related Disease Score Top Affiliating Genes
1 gastrointestinal stromal tumor 29.2 EGFR PDGFRA SYP TP53
2 glassy cell variant cervical adenosquamous carcinoma 12.1
3 endometrial adenosquamous carcinoma 12.1
4 gastric adenosquamous carcinoma 12.1
5 cervical adenosquamous carcinoma 12.1
6 esophageal adenosquamous carcinoma 12.0
7 thymus adenosquamous carcinoma 11.9
8 bartholin's gland adenosquamous carcinoma 11.9
9 ampulla of vater adenosquamous carcinoma 11.9
10 adenosquamous cell lung carcinoma 11.1
11 adenosquamous colon carcinoma 11.1
12 adenosquamous gallbladder carcinoma 11.0
13 adenosquamous prostate carcinoma 11.0
14 adenosquamous pancreas carcinoma 11.0
15 adenosquamous bile duct carcinoma 10.8
16 adenocarcinoma 10.5
17 cervicitis 10.3
18 pancreatitis 10.3
19 invasive mole 10.3 MUC1 PDGFRA
20 cervical lymphoepithelioma-like carcinoma 10.3 EGFR MUC1
21 severe pre-eclampsia 10.3 EGFR KRAS
22 immunodeficiency due to a classical component pathway complement deficiency 10.3 EGFR MUC1
23 squamous cell carcinoma 10.3
24 agenesis and aplasia of uterine body 10.3 EGFR KRAS
25 kidney clear cell sarcoma 10.2 EGFR KRAS PDGFRA
26 prostatitis 10.2
27 precursor t-lymphoblastic lymphoma/leukemia 10.2 EGFR KRAS MUC1
28 vascular hemostatic disease 10.2 EGFR KRAS PDGFRA
29 wolffian adnexal neoplasm 10.2 EGFR TP53
30 intermediate malignant teratoma 10.2 EGFR KRAS KRT5
31 sengers syndrome 10.2 EGFR MUC1 PDGFRA
32 spastic diplegia infantile type 10.2 EGFR KRAS MUC1
33 biliary papillomatosis 10.2 KRAS MUC1
34 laryngeal mucoepidermoid carcinoma 10.2 KRT5 MUC1 MUC4
35 breast ductal carcinoma 10.2 KRAS TP53
36 camptomelic syndrome long limb type 10.2 KRT8 TP53
37 occipital encephalocele 10.2 KRT18 KRT8
38 lung combined type small cell carcinoma 10.2 KRT5 MUC1 TP63
39 woolly hair, autosomal dominant 10.1 KRT18 KRT8
40 proteus-like syndrome 10.1 KRT18 KRT8
41 multidrug-resistant tuberculosis 10.1 KRT18 KRT5
42 mitochondrial neurogastrointestinal encephalopathy disease 10.1 KRAS TP53
43 basaloid squamous cell carcinoma 10.1 EGFR KRT5 PTHLH
44 reticulosarcoma 10.1 AR TP53
45 interstitial lung disease 10.1 EGFR PDGFRA TP53
46 myxedema 10.1 EGFR KRAS TP53
47 lymphedema 10.1 MUC1 MUC4 TP63
48 nervous system hibernoma 10.1 AR EGFR
49 odontotrichoungual-digital-palmar syndrome 10.1 KRT8 MUC1 MUC4
50 papillary adenofibroma 10.1 KRAS MUC1 TP53

Graphical network of the top 20 diseases related to Adenosquamous Carcinoma:



Diseases related to Adenosquamous Carcinoma

Symptoms & Phenotypes for Adenosquamous Carcinoma

MGI Mouse Phenotypes related to Adenosquamous Carcinoma:

44 (show all 19)
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.24 AR EGFR KRAS KRT18 KRT5 KRT8
2 digestive/alimentary MP:0005381 10.22 PDGFRA PTHLH TP53 TP63 AR EGFR
3 cardiovascular system MP:0005385 10.19 AR EGFR KRAS KRT8 PDGFRA PTHLH
4 craniofacial MP:0005382 10.18 AR EGFR KRAS KRT5 PDGFRA PTHLH
5 mortality/aging MP:0010768 10.18 AR EGFR KRAS KRT18 KRT5 KRT8
6 embryo MP:0005380 10.16 AR EGFR KRAS KRT18 KRT8 PDGFRA
7 integument MP:0010771 10.13 EGFR KRAS KRT5 PDGFRA PTHLH TP53
8 limbs/digits/tail MP:0005371 10.11 AR EGFR KRAS KRT5 PDGFRA PTHLH
9 endocrine/exocrine gland MP:0005379 10.09 PDGFRA PTHLH TP53 TP63 AR EGFR
10 liver/biliary system MP:0005370 9.97 TP53 AR EGFR KRAS KRT18 KRT8
11 muscle MP:0005369 9.93 AR EGFR KRAS PDGFRA TP53 TP63
12 neoplasm MP:0002006 9.91 EGFR KRAS PDGFRA TP53 TP63 AR
13 normal MP:0002873 9.91 AR EGFR KRAS PDGFRA SYP TP53
14 no phenotypic analysis MP:0003012 9.88 TP53 TP63 EGFR KRAS KRT5 PDGFRA
15 renal/urinary system MP:0005367 9.8 AR EGFR KRAS PDGFRA PTHLH TP53
16 reproductive system MP:0005389 9.76 AR EGFR KRAS KRT8 PDGFRA PTHLH
17 pigmentation MP:0001186 9.72 AR EGFR KRAS PDGFRA TP53
18 respiratory system MP:0005388 9.43 EGFR KRAS PDGFRA PTHLH TP53 TP63
19 skeleton MP:0005390 9.17 AR EGFR KRAS PDGFRA PTHLH TP53

Drugs & Therapeutics for Adenosquamous Carcinoma

Drugs for Adenosquamous Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 173)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
2 Hematinics Phase 4,Phase 3,Phase 2
3 Epoetin alfa Phase 4,Phase 3 113427-24-0
4
Gefitinib Approved, Investigational Phase 3,Phase 2,Phase 1 184475-35-2 123631
5
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
6
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
7
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
8
Succinylcholine Approved Phase 3,Phase 1,Phase 2 306-40-1 5314
9
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
10
Vinblastine Approved Phase 3 865-21-4 13342 241903
11
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
12
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
13
Doxorubicin Approved, Investigational Phase 3,Phase 1 23214-92-8 31703
14
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
15
Bleomycin Approved Phase 3 11056-06-7 5360373
16
Fluorouracil Approved Phase 3,Phase 1,Phase 2 51-21-8 3385
17
Ifosfamide Approved Phase 3 3778-73-2 3690
18
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
19
Vindesine Approved Phase 3 59917-39-4, 53643-48-4 40839
20
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
21
Celecoxib Approved, Investigational Phase 3,Phase 1,Phase 2 169590-42-5 2662
22
Pemetrexed Approved, Investigational Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
23
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
24
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
25
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
26
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
27
Tirapazamine Investigational Phase 3,Phase 2,Phase 1 27314-97-2
28
Doxil Approved June 1999 Phase 3,Phase 1 31703
29
Erlotinib Hydrochloride Phase 3,Phase 2,Phase 1 183319-69-9 176871
30 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
31 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
32 Anti-Infective Agents Phase 3,Phase 2,Phase 1
33 Antimetabolites Phase 3,Phase 2,Phase 1
34 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
35 Antimitotic Agents Phase 3,Phase 2,Phase 1
36 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
37 Antiviral Agents Phase 3,Phase 2,Phase 1
38 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
39 Antibodies Phase 3,Phase 2,Phase 1
40 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
41 Immunoglobulins Phase 3,Phase 2,Phase 1
42 Folic Acid Antagonists Phase 3,Phase 2,Phase 1
43 Vitamin B Complex Phase 3,Phase 2,Phase 1
44 insulin Phase 3
45 Insulin, Globin Zinc Phase 3
46 Neuromuscular Agents Phase 3,Phase 1,Phase 2
47 Neuromuscular Blocking Agents Phase 3,Phase 1,Phase 2
48 Neuromuscular Depolarizing Agents Phase 3,Phase 1,Phase 2
49 Peripheral Nervous System Agents Phase 3,Phase 1,Phase 2
50 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 173)
id Name Status NCT ID Phase
1 Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Completed NCT00046969 Phase 4
2 Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT00955695 Phase 3
3 Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Completed NCT00064077 Phase 3
4 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00803062 Phase 3
5 Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer Completed NCT00262821 Phase 3
6 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3
7 Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia Completed NCT00017004 Phase 3
8 Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00003945 Phase 3
9 Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer Completed NCT00003209 Phase 3
10 Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery Completed NCT00002807 Phase 3
11 Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix Completed NCT00003078 Phase 3
12 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3
13 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3
14 Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Completed NCT00002852 Phase 3
15 Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00005838 Phase 3
16 Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00002623 Phase 3
17 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Completed NCT00049543 Phase 3
18 Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer Completed NCT00003117 Phase 3
19 Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer Completed NCT00002823 Phase 3
20 Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer Completed NCT00003685 Phase 3
21 Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery Recruiting NCT01101451 Phase 3
22 Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Recruiting NCT01414608 Phase 3
23 Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Recruiting NCT00980954 Phase 3
24 Laparoscopic Approach to Cervical Cancer Recruiting NCT00614211 Phase 3
25 Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix Active, not recruiting NCT01365156 Phase 3
26 Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy in Patients With Stage IB or II Cervical Cancer Active, not recruiting NCT00039338 Phase 3
27 Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer Active, not recruiting NCT00499330 Phase 3
28 Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer Active, not recruiting NCT01041781 Phase 3
29 Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology Terminated NCT00596830 Phase 3
30 Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer Terminated NCT00673049 Phase 3
31 Evaluation of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer Terminated NCT01363466 Phase 3
32 Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix Terminated NCT00054067 Phase 3
33 Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer Terminated NCT00085631 Phase 3
34 Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy Terminated NCT01208064 Phase 2, Phase 3
35 Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer Terminated NCT00863512 Phase 3
36 Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer Terminated NCT00004859 Phase 3
37 Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Withdrawn NCT00054392 Phase 3
38 Cisplatin Combined With Radiation Therapy and Hyperthermia in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer Unknown status NCT00008112 Phase 2
39 Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer Unknown status NCT01158248 Phase 2
40 Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer Unknown status NCT01230996 Phase 1, Phase 2
41 Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Unknown status NCT00462397 Phase 2
42 Docetaxel in Treating Older Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Unknown status NCT00227708 Phase 2
43 Gemcitabine and Cisplatin Before or After Surgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer Unknown status NCT00398385 Phase 2
44 Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Unknown status NCT00033722 Phase 2
45 Bryostatin-1 Plus Cisplatin in Treating Patients With Recurrent or Advanced Cancer of the Cervix Completed NCT00005965 Phase 2
46 Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00039442 Phase 2
47 Ixabepilone to Treat Cervical Cancer Completed NCT00924066 Phase 2
48 Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck Completed NCT00570674 Phase 1, Phase 2
49 Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01011933 Phase 2
50 Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00820898 Phase 2

Search NIH Clinical Center for Adenosquamous Carcinoma

Cochrane evidence based reviews: carcinoma, adenosquamous

Genetic Tests for Adenosquamous Carcinoma

Anatomical Context for Adenosquamous Carcinoma

MalaCards organs/tissues related to Adenosquamous Carcinoma:

39
Pancreas, Lung, Cervix, Breast, Liver, Colon, Prostate

Publications for Adenosquamous Carcinoma

Articles related to Adenosquamous Carcinoma:

(show top 50) (show all 505)
id Title Authors Year
1
Prognostic factors and adjuvant therapy on survival in early-stage cervical adenocarcinoma/adenosquamous carcinoma after primary radical surgery: A Taiwanese Gynecologic Oncology Group (TGOG) study. ( 27566027 )
2016
2
Oral Adenosquamous Carcinoma Mimicking a Pyogenic Granuloma: a Challenging Diagnosis. ( 27982195 )
2016
3
Adenosquamous carcinoma of the tongue: clinicopathologic study and review of the literature. ( 27456683 )
2016
4
Comment on: Prognostic factors and adjuvant therapy on survival in early-stage cervical adenocarcinoma/adenosquamous carcinoma after primary radical surgery: A Taiwanese Gynecologic Oncology Group (TGOG) study. ( 27793441 )
2016
5
A Case of Pancreatic Adenosquamous Carcinoma Obstructing the Common Bile and Pancreatic Ducts, Duodenum, and Gastric Outlet. ( 26863381 )
2016
6
Adenosquamous carcinoma arising from a thyroglossal duct cyst: A case report. ( 27073536 )
2016
7
Adenosquamous carcinoma of pancreas: CT and MR imaging features in eight patients, with pathologic correlations and comparison with adenocarcinoma of pancreas. ( 27039322 )
2016
8
Serum carbohydrate antigen 12-5 level enhances the prognostic value in primary adenosquamous carcinoma of the lung: a two-institutional experience. ( 27002010 )
2016
9
Adenosquamous Carcinoma of the Head and Neck: A Case-Control Study with Conventional Squamous Cell Carcinoma. ( 27169400 )
2016
10
Adenosquamous Carcinoma of the Duodenum: a Rare Entity. ( 27872539 )
2016
11
Primary adenosquamous carcinoma of the esophagus: an analysis of 39 cases. ( 27867543 )
2016
12
Comparison of clinical outcomes of squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma of the uterine cervix after definitive radiotherapy: a population-based analysis. ( 27646608 )
2016
13
S100P is Overexpressed in Squamous Cell and Adenosquamous Carcinoma Subtypes of Endometrial Cancer and Promotes Cancer Cell Proliferation and Invasion. ( 27918216 )
2016
14
Nab-paclitaxel+gemcitabine therapy for adenosquamous carcinoma of the pancreas: an autopsy case. ( 27725467 )
2016
15
Primary cutaneous adenosquamous carcinoma of the penis: the first characterization of HPV status in this rare and diagnostically challenging entity with review of glandular carcinomas of the penis. ( 27696488 )
2016
16
Improved survival associated with a balanced structure between adenomatous and squamous components in patients with adenosquamous carcinoma of the lung. ( 27365198 )
2016
17
Cervical adenosquamous carcinoma with extension to uterine corpus. ( 27306573 )
2016
18
Analysis of SEER Adenosquamous Carcinoma Data to Identify Cause Specific Survival Predictors and Socioeconomic Disparities. ( 26838235 )
2016
19
A case of adenosquamous carcinoma of the lower bile duct diagnosed preoperatively via transpapillary biopsy. ( 27498940 )
2016
20
Tracking the Clonal Evolution of Adenosquamous Carcinoma, a Rare Variant of Intraductal Papillary Mucinous Neoplasm of the Pancreas. ( 27295533 )
2016
21
Intraluminal superior vena cava metastasis from adenosquamous carcinoma of the duodenum: A case report. ( 26870254 )
2016
22
Impact of histological subtype on survival in patients with locally advanced cervical cancer that were treated with definitive radiotherapy: adenocarcinoma/adenosquamous carcinoma versus squamous cell carcinoma. ( 28028992 )
2016
23
Characterization of primary pulmonary adenosquamous carcinoma-associated pleural effusion. ( 26797868 )
2016
24
A case of ovarian adenosquamous carcinoma arising from endometrioid adenocarcinoma: a case report and systematic review. ( 27514842 )
2016
25
MCM2 and TIP30 are prognostic markers in squamous cell/adenosquamous carcinoma and adenocarcinoma of the gallbladder. ( 27748889 )
2016
26
The Squamous Cells of Adenosquamous Carcinoma (ASCC) of the Prostate Might Represent a Terminally Differentiated Quiescent Component: Immunohistochemical Evidence From a Case of ASCC With Pleomorphic Giant Tumor Cells. ( 27753662 )
2016
27
Adenosquamous carcinoma in the biliary tract: association of the proliferative ability of the squamous component with its proportion and tumor progression. ( 28034323 )
2016
28
(18)F-FDG PET/CT in a case of primary hepatic adenosquamous carcinoma. ( 27033745 )
2016
29
Oral adenosquamous carcinoma: Report of a rare entity with a special insight on its histochemistry. ( 27721632 )
2016
30
Primary Colon Adenosquamous Carcinoma in a Patient With Lynch Syndrome: A New Histologic Subtype Associated With Microsatellite Instability? ( 27422471 )
2016
31
Is cervical screening preventing adenocarcinoma and adenosquamous carcinoma of the cervix? ( 27096255 )
2016
32
Primary adenosquamous carcinoma of the liver: a case report. ( 28081592 )
2016
33
Reply: Prognostic factors and impact of adjuvant therapy on survival in early-stage cervical adenocacinoma and adenosquamous carcinoma after primary radical hysterectomy and pelvic lymphadenectomy. ( 27726945 )
2016
34
Low-grade adenosquamous carcinoma of the breast: A diagnostic andA clinical challenge. ( 25986061 )
2015
35
Adenosquamous carcinoma of the head and neck: Molecular analysis using CRTC-MAML FISH and survival comparison with paired conventional squamous cell carcinoma. ( 26255977 )
2015
36
Salvage pancreaticoduodenectomy after complete response to chemoradiotherapy for a previously unresectable pancreatic adenosquamous carcinoma: a case report. ( 25674740 )
2015
37
Metastatic Squamous Cell Carcinoma Component from an Adenosquamous Carcinoma of the Lung with Identical Epidermal Growth Factor Receptor Mutations. ( 26366316 )
2015
38
Adenosquamous carcinoma of oral cavity. ( 26881633 )
2015
39
Low-Grade Adenosquamous Carcinoma of the Breast Developing Around a Localization Wire Fragment. ( 26199266 )
2015
40
A Comparison of Adenosquamous Carcinoma and Adenocarcinoma of the Cervix after Radical Hysterectomy. ( 25661329 )
2015
41
Laryngeal adenosquamous carcinoma: A population-based perspective. ( 26452061 )
2015
42
Differences in the ARID-1 alpha expressions in squamous and adenosquamous carcinomas of uterine cervix. ( 26303865 )
2015
43
Adenosquamous Carcinoma of the Esophagus and Esophagogastric Junction: Clinical Manifestations and Treatment Outcomes. ( 25967141 )
2015
44
Gallbladder Adenosquamous Carcinoma Associated with Biliopancreatic Maljunction and Cystic Metastases of the Liver Miming Abscess. ( 27011570 )
2015
45
CD109 is a novel marker for squamous cell/adenosquamous carcinomas of the gallbladder. ( 26249215 )
2015
46
Adenosquamous carcinoma of the oesophagus in a dog. ( 25622695 )
2015
47
Adenosquamous carcinoma of the ampulla of Vater: a case report and literature review. ( 26420726 )
2015
48
Stereotactic aspiration combined with gamma knife radiosurgery for the treatment of cystic brainstem metastasis originating from lung adenosquamous carcinoma: A case report. ( 25789009 )
2015
49
Fatal submucosal invasive gastric adenosquamous carcinoma detected at surveillance after gastric endoscopic submucosal dissection. ( 25892891 )
2015
50
Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas. ( 25830031 )
2015

Variations for Adenosquamous Carcinoma

Expression for Adenosquamous Carcinoma

Search GEO for disease gene expression data for Adenosquamous Carcinoma.

Pathways for Adenosquamous Carcinoma

Pathways related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

(show all 23)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.82 AR EGFR KRAS PDGFRA TP53
2 12.54 EGFR KRAS PDGFRA TP53
3
Show member pathways
12.47 EGFR KRAS PDGFRA TP53
4 12.39 EGFR KRAS PDGFRA TP53
5
Show member pathways
12.38 EGFR KRAS PDGFRA TP53
6
Show member pathways
12.34 EGFR KRAS MUC1 TP53
7 12.32 AR EGFR KRAS PDGFRA TP53
8 12.28 KRT18 KRT5 KRT8 MUC1
9
Show member pathways
12.25 EGFR KRAS PDGFRA TP53
10
Show member pathways
12.18 EGFR KRAS PDGFRA TP53
11 12.03 EGFR KRAS PDGFRA TP53 TP63
12
Show member pathways
11.92 EGFR KRAS TP53
13 11.89 EGFR TP53 TP63
14 11.88 EGFR KRAS TP53
15
Show member pathways
11.88 EGFR KRAS PDGFRA TP53
16 11.75 AR EGFR KRAS TP53
17
Show member pathways
11.73 KRT18 KRT5 KRT8
18 11.47 EGFR KRAS TP53
19 11.3 EGFR KRAS PDGFRA TP53
20 11.29 EGFR PDGFRA TP53
21 11.1 EGFR KRAS TP53
22
Show member pathways
10.95 TP53 TP63
23 10.74 EGFR KRAS PDGFRA TP53

GO Terms for Adenosquamous Carcinoma

Cellular components related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.7 AR EGFR KRAS KRT18 KRT5 KRT8
2 keratin filament GO:0045095 9.33 KRT18 KRT5 KRT8
3 nuclear chromatin GO:0000790 8.92 AR MUC1 TP53 TP63

Biological processes related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

(show all 15)
id Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.85 KRT18 KRT8 PDGFRA TP53
2 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.69 KRAS MUC1 MUC4
3 phosphatidylinositol-mediated signaling GO:0048015 9.67 EGFR PDGFRA TP53
4 cornification GO:0070268 9.65 KRT18 KRT5 KRT8
5 positive regulation of cell proliferation GO:0008284 9.65 AR EGFR KRAS PDGFRA PTHLH
6 female pregnancy GO:0007565 9.61 KRAS MUC1 PTHLH
7 response to X-ray GO:0010165 9.54 TP53 TP63
8 regulation of long-term neuronal synaptic plasticity GO:0048169 9.52 KRAS SYP
9 hepatocyte apoptotic process GO:0097284 9.46 KRT18 KRT8
10 Leydig cell differentiation GO:0033327 9.4 AR PDGFRA
11 mitotic G1 DNA damage checkpoint GO:0031571 9.37 TP53 TP63
12 prostate gland development GO:0030850 9.32 AR TP63
13 epidermis development GO:0008544 9.26 EGFR KRT5 PTHLH TP63
14 morphogenesis of an epithelial fold GO:0060571 9.16 AR EGFR
15 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.8 MUC1 TP53 TP63

Molecular functions related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 chromatin binding GO:0003682 9.46 AR EGFR TP53 TP63
2 p53 binding GO:0002039 9.13 MUC1 TP53 TP63
3 scaffold protein binding GO:0097110 8.8 KRT18 KRT5 KRT8

Sources for Adenosquamous Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....